CCCC Historical Financial Ratios

CCCC Stock

USD 2.65 0.14 5.02%

C4 Therapeutics is presently reporting on over 100 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 1.08 or Days Sales Outstanding of 372 will help investors to properly organize and evaluate C4 Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.

About CCCC Financial Ratios Analysis

C4 TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate C4 Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on CCCC financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across C4 Therapeutics history.

C4 Therapeutics Financial Ratios Chart

At present, C4 Therapeutics' PTB Ratio is projected to increase based on the last few years of reporting. The current year's Days Sales Outstanding is expected to grow to 371.78, whereas Book Value Per Share is forecasted to decline to 2.38.

Price To Sales Ratio Days Sales Outstanding Ev To Sales Payables Turnover Operating Cycle

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing C4 Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on C4 Therapeutics sales, a figure that is much harder to manipulate than other C4 Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from C4 Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into C4 Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.At present, C4 Therapeutics' PTB Ratio is projected to increase based on the last few years of reporting. The current year's Days Sales Outstanding is expected to grow to 371.78, whereas Book Value Per Share is forecasted to decline to 2.38.

	2022	2023	2024	2025 (projected)
Graham Number	18.57	17.26	15.53	11.72
Receivables Turnover	21.11	1.76	1.58	1.5

Graham Number Receivables Turnover

C4 Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		-0.01	-0.42	0.19	0.4	0.52	-0.66	-0.01	0.91	0.58	-0.17	-0.13	0.19	-0.06	-0.28	-0.09	-0.72	0.24	0.38	0.16	0.53	0.37	0.25	-0.67	0.12	0.39
Ptb Ratio	-0.01		-0.65	0.89	-0.57	-0.79	-0.42	1.0	-0.13	-0.75	-0.29	0.29	-0.72	-0.91	0.25	-0.32	-0.56	0.93	0.01	-0.4	0.56	-0.08	0.4	0.33	-0.83	0.02
Days Sales Outstanding	-0.42	-0.65		-0.92	0.53	0.25	0.6	-0.65	-0.31	0.17	0.74	-0.31	0.68	0.85	-0.16	0.31	0.71	-0.77	-0.73	0.44	-0.98	-0.67	-0.36	0.47	0.76	-0.73
Book Value Per Share	0.19	0.89	-0.92		-0.6	-0.55	-0.53	0.89	0.1	-0.48	-0.56	0.32	-0.76	-0.96	0.19	-0.28	-0.67	0.91	0.43	-0.42	0.84	0.35	0.49	-0.09	-0.86	0.43
Free Cash Flow Yield	0.4	-0.57	0.53	-0.6		0.77	0.11	-0.57	0.62	0.74	0.76	-0.62	0.96	0.77	-0.74	0.65	0.1	-0.37	-0.43	0.88	-0.48	-0.39	0.14	-0.05	0.91	-0.44
Operating Cash Flow Per Share	0.52	-0.79	0.25	-0.55	0.77		0.03	-0.79	0.69	1.0	0.24	-0.43	0.78	0.71	-0.54	0.49	0.08	-0.52	0.19	0.59	-0.15	0.25	-0.12	-0.62	0.78	0.18
Capex To Depreciation	-0.66	-0.42	0.6	-0.53	0.11	0.03		-0.42	-0.5	-0.04	0.47	-0.36	0.31	0.5	-0.35	0.33	0.96	-0.5	-0.39	0.39	-0.72	-0.34	-0.26	0.38	0.4	-0.41
Pb Ratio	-0.01	1.0	-0.65	0.89	-0.57	-0.79	-0.42		-0.13	-0.75	-0.29	0.29	-0.72	-0.91	0.25	-0.32	-0.56	0.93	0.01	-0.4	0.56	-0.08	0.4	0.33	-0.83	0.02
Ev To Sales	0.91	-0.13	-0.31	0.1	0.62	0.69	-0.5	-0.13		0.74	0.07	-0.27	0.44	0.12	-0.57	0.31	-0.57	0.2	0.27	0.47	0.38	0.27	0.33	-0.6	0.33	0.27
Free Cash Flow Per Share	0.58	-0.75	0.17	-0.48	0.74	1.0	-0.04	-0.75	0.74		0.18	-0.41	0.74	0.65	-0.52	0.47	0.01	-0.46	0.25	0.55	-0.07	0.31	-0.09	-0.67	0.73	0.25
Roic	-0.17	-0.29	0.74	-0.56	0.76	0.24	0.47	-0.29	0.07	0.18		-0.6	0.79	0.66	-0.64	0.68	0.43	-0.25	-0.88	0.84	-0.8	-0.85	0.09	0.59	0.74	-0.89
Inventory Turnover	-0.13	0.29	-0.31	0.32	-0.62	-0.43	-0.36	0.29	-0.27	-0.41	-0.6		-0.62	-0.48	0.6	-0.65	-0.27	0.14	0.32	-0.72	0.36	0.3	-0.12	-0.07	-0.57	0.33
Net Income Per Share	0.19	-0.72	0.68	-0.76	0.96	0.78	0.31	-0.72	0.44	0.74	0.79	-0.62		0.9	-0.68	0.71	0.35	-0.55	-0.46	0.86	-0.65	-0.4	-0.08	0.0	0.98	-0.47
Days Of Inventory On Hand	-0.06	-0.91	0.85	-0.96	0.77	0.71	0.5	-0.91	0.12	0.65	0.66	-0.48	0.9		-0.42	0.51	0.6	-0.84	-0.41	0.64	-0.8	-0.33	-0.31	0.01	0.96	-0.42
Payables Turnover	-0.28	0.25	-0.16	0.19	-0.74	-0.54	-0.35	0.25	-0.57	-0.52	-0.64	0.6	-0.68	-0.42		-0.68	-0.17	0.01	0.27	-0.93	0.25	0.25	-0.39	0.03	-0.61	0.29
Average Inventory	-0.09	-0.32	0.31	-0.28	0.65	0.49	0.33	-0.32	0.31	0.47	0.68	-0.65	0.71	0.51	-0.68		0.32	-0.11	-0.35	0.82	-0.39	-0.32	0.13	0.15	0.61	-0.36
Capex To Revenue	-0.72	-0.56	0.71	-0.67	0.1	0.08	0.96	-0.56	-0.57	0.01	0.43	-0.27	0.35	0.6	-0.17	0.32		-0.66	-0.37	0.29	-0.79	-0.32	-0.45	0.35	0.46	-0.39
Cash Per Share	0.24	0.93	-0.77	0.91	-0.37	-0.52	-0.5	0.93	0.2	-0.46	-0.25	0.14	-0.55	-0.84	0.01	-0.11	-0.66		0.13	-0.19	0.68	0.04	0.43	0.12	-0.7	0.14
Pocfratio	0.38	0.01	-0.73	0.43	-0.43	0.19	-0.39	0.01	0.27	0.25	-0.88	0.32	-0.46	-0.41	0.27	-0.35	-0.37	0.13		-0.49	0.79	1.0	-0.02	-0.87	-0.43	1.0
Interest Coverage	0.16	-0.4	0.44	-0.42	0.88	0.59	0.39	-0.4	0.47	0.55	0.84	-0.72	0.86	0.64	-0.93	0.82	0.29	-0.19	-0.49		-0.5	-0.46	0.27	0.13	0.8	-0.5
Capex To Operating Cash Flow	0.53	0.56	-0.98	0.84	-0.48	-0.15	-0.72	0.56	0.38	-0.07	-0.8	0.36	-0.65	-0.8	0.25	-0.39	-0.79	0.68	0.79	-0.5		0.73	0.31	-0.58	-0.71	0.8
Pfcf Ratio	0.37	-0.08	-0.67	0.35	-0.39	0.25	-0.34	-0.08	0.27	0.31	-0.85	0.3	-0.4	-0.33	0.25	-0.32	-0.32	0.04	1.0	-0.46	0.73		-0.06	-0.89	-0.36	0.99
Days Payables Outstanding	0.25	0.4	-0.36	0.49	0.14	-0.12	-0.26	0.4	0.33	-0.09	0.09	-0.12	-0.08	-0.31	-0.39	0.13	-0.45	0.43	-0.02	0.27	0.31	-0.06		0.05	-0.14	-0.04
Income Quality	-0.67	0.33	0.47	-0.09	-0.05	-0.62	0.38	0.33	-0.6	-0.67	0.59	-0.07	0.0	0.01	0.03	0.15	0.35	0.12	-0.87	0.13	-0.58	-0.89	0.05		-0.03	-0.87
Roe	0.12	-0.83	0.76	-0.86	0.91	0.78	0.4	-0.83	0.33	0.73	0.74	-0.57	0.98	0.96	-0.61	0.61	0.46	-0.7	-0.43	0.8	-0.71	-0.36	-0.14	-0.03		-0.44
Ev To Operating Cash Flow	0.39	0.02	-0.73	0.43	-0.44	0.18	-0.41	0.02	0.27	0.25	-0.89	0.33	-0.47	-0.42	0.29	-0.36	-0.39	0.14	1.0	-0.5	0.8	0.99	-0.04	-0.87	-0.44

Click cells to compare fundamentals

C4 Therapeutics Account Relationship Matchups

C4 Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	42.98	32.38	9.27	13.51	15.54	30.95
Ptb Ratio	5.08	3.81	1.0	1.14	1.03	1.08
Days Sales Outstanding	49.3	45.57	17.29	207.49	238.61	371.78
Book Value Per Share	6.52	8.46	5.92	4.96	4.46	2.38
Free Cash Flow Yield	0.0495	(0.0476)	(0.0595)	(0.39)	(0.45)	(0.42)
Operating Cash Flow Per Share	(1.56)	(1.89)	(2.17)	(2.15)	(2.48)	(2.6)
Stock Based Compensation To Revenue	0.1	0.47	0.97	1.31	1.18	1.24
Capex To Depreciation	0.4	0.86	3.28	0.91	0.82	1.12
Pb Ratio	5.08	3.81	1.0	1.14	1.03	1.08
Ev To Sales	38.19	31.65	11.12	10.83	12.46	11.84
Free Cash Flow Per Share	(1.58)	(1.92)	(2.28)	(2.19)	(2.51)	(2.64)
Roic	(0.17)	(0.18)	(0.32)	(0.41)	(0.48)	(0.5)
Net Income Per Share	(1.54)	(1.87)	(2.59)	(2.67)	(3.07)	(3.22)
Payables Turnover	13.63	0.65	6.46	81.4	73.26	76.92
Sales General And Administrative To Revenue	0.46	0.73	1.38	2.03	1.82	1.92
Research And Ddevelopement To Revenue	2.36	2.07	3.79	5.67	5.1	5.36
Capex To Revenue	0.0196	0.0279	0.18	0.0823	0.0741	0.0678
Cash Per Share	8.63	6.72	5.65	5.11	4.6	4.09
Pocfratio	(21.21)	(17.05)	(2.72)	(2.63)	(2.36)	(2.48)
Capex To Operating Cash Flow	(0.009666)	(0.0147)	(0.0519)	(0.016)	(0.0144)	(0.0151)
Pfcf Ratio	(21.01)	(16.8)	(2.59)	(2.58)	(2.33)	(2.44)
Days Payables Outstanding	26.78	565.77	56.49	4.48	4.04	3.83
Income Quality	1.01	1.04	0.83	0.81	0.73	0.42
Roe	(0.24)	(0.22)	(0.44)	(0.54)	(0.62)	(0.59)
Ev To Operating Cash Flow	(18.85)	(16.67)	(3.26)	(2.1)	(1.89)	(1.99)
Pe Ratio	(21.51)	(17.23)	(2.28)	(2.12)	(1.91)	(2.0)
Ev To Free Cash Flow	(18.67)	(16.42)	(3.1)	(2.07)	(1.86)	(1.96)
Earnings Yield	(0.0465)	(0.058)	(0.44)	(0.47)	(0.54)	(0.52)
Net Debt To E B I T D A	2.53	0.42	(0.46)	0.46	0.52	0.5
Current Ratio	8.69	6.36	6.46	6.34	5.71	4.78
Tangible Book Value Per Share	6.52	8.46	5.92	4.96	4.46	2.38
Receivables Turnover	7.4	8.01	21.11	1.76	1.58	1.5
Graham Number	15.03	18.86	18.57	17.26	15.53	11.72
Shareholders Equity Per Share	6.52	8.46	5.92	4.96	4.46	2.38
Debt To Equity	0.0816	0.11	0.3	0.29	0.26	0.27
Capex Per Share	0.0151	0.0277	0.11	0.0344	0.0396	0.0739
Graham Net Net	5.94	4.27	2.15	2.66	2.4	2.52

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:

How To Invest In CCCC

Details

Is CCCC Stock a good investment?

Details

What is C4 Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.

You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.71)

Revenue Per Share

0.522

Quarterly Revenue Growth

0.387

Return On Assets

(0.21)

Return On Equity

(0.46)

The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

CCCC Historical Financial Ratios

About CCCC Financial Ratios Analysis

C4 Therapeutics Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Payables Turnover

C4 Therapeutics fundamentals Correlations

C4 Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

C4 Therapeutics fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 0.99	Pfcf Ratio
Roe	+ 0.98	Net Income Per Share

Capex To Operating Cash Flow	- 0.98	Days Sales Outstanding
Days Of Inventory On Hand	- 0.96	Book Value Per Share
Interest Coverage	- 0.93	Payables Turnover
Book Value Per Share	- 0.92	Days Sales Outstanding
Days Of Inventory On Hand	- 0.91	Pb Ratio
Days Of Inventory On Hand	- 0.91	Ptb Ratio